PHILADELPHIA, Aug. 24, 2026 (GLOBE NEWSWIRE) —
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY):
Grabar Law Office is investigating claims on behalf of shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY).
What is The Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) shares prior to March 9, 2026, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. Please visit https://grabarlaw.com/the-latest/ars-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.
What is Alleged? It is alleged in a recently filed federal securities fraud class action complaint that ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) certain corporate officers knew or recklessly disregarded potential timeline issues with CVS Caremark’s formulary addition and coverage decision related to neffy; (ii) the guidance ARS Pharmaceuticals provided to investors related to the timeline for expansion of insurance coverage for neffy with CVS Caremark may be significantly shifted, impacting commercialization efforts; and (iii) the expanded insurance coverage may not be available by the July 1 deadline, thus, ARS Pharmaceuticals would not have the expanded insurance coverage for neffy with CVS Caremark for the summer and back-to-school seasons.
On June 24, 2026, after the market closed, ARS Pharmaceuticals published a press release announcing that ARS Pharmaceuticals did not receive expanded insurance coverage for neffy through CVS Caremark by the guided July 1, 2026 deadline, which meant that ARS Pharmaceuticals did not have expanded insurance coverage for neffy for the summer or back-to-school allergy seasons. ARS Pharmaceuticals allegedly also stated that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027. On this news, the price of ARS Pharmaceuticals stock declined nearly 24%, according to the complaint.
What Can You Do Now? If you purchased ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) shares prior to March 9, 2026, and still hold shares today, please visit https://grabarlaw.com/the-latest/ars-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. #SPRY $SPRY #ARSPharmaceuticals
Roblox Corporation (NYSE: RBLX):
Grabar Law Office is investigating claims on behalf of shareholders of Roblox Corporation (NYSE: RBLX).
What is The Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased Roblox Corporation (NYSE: RBLX), shares prior to October 31, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/roblox-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
What is Alleged? A recently filed securities fraud class action complaint alleges that Roblox Corporation (NYSE: RBLX) via certain of its officers, made material misrepresentations to investors concerning Roblox’s anticipated earnings growth. Specifically, Roblox stated that 2026 bookings would grow by 22% to 26%, which reflected Roblox’s “confidence in the adoption of our age-checking technology.” Roblox also stated that its age verification features provided “a bigger growth opportunity in the 18-plus demographic than previously assumed” and stated that its “18 and over cohort is growing at over 50%[.]” In truth, as alleged, Roblox’s age verification rollout was causing a slowdown in on-platform communication, app store rating reductions, and a considerable reduction in organic growth.
What Can You Do Now? If you purchased Roblox Corporation (NYSE: RBLX) shares prior to October 31, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/roblox-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Roblox #RBLX $RBLX
Symbotic Inc. (NASDAQ: SYM) Shareholder Class Action Survives Motion to Dismiss:
Grabar Law Office is investigating claims on behalf of investors who purchased or otherwise acquired Symbotic Inc. (NASDAQ: SYM) securities on or before February 5, 2024.
What is Happening? Key allegations of a federal securities fraud class action have survived Defendants’ motion to dismiss the complaint. The investigation follows a recent federal court decision permitting significant securities fraud claims against Symbotic and its Chairman and Chief Executive Officer, Richard B. Cohen, to proceed. Specifically, on July 23, 2026, Chief Judge Denise J. Casper of the United States District Court for the District of Massachusetts denied in part defendants’ motion to dismiss a securities fraud class action against Symbotic and certain of its senior executives.
If you purchased Symbotic Inc. (NASDAQ: SYM) shares on or prior to February 5, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/symbotic-shareholder-investigation/, contact Joshua H. Grabar of Grabar Law Office at jgrabar@grabarlaw.com, or call 267-507-6085 to discuss your rights. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
What is Alleged? The underlying securities fraud class action alleges that Symbotic Inc. (NASDAQ: SYM), through certain executives, misled investors concerning the Company’s progress in accelerating deployment of its warehouse automation systems. Among other things, it is alleged that Symbotic repeatedly represented that it was successfully accelerating system deployments even though the Company’s average system deployment time allegedly remained approximately 24 months and its primary engineering, procurement and construction outsourcing partner was experiencing significant operational problems.
What Did the Court Hold? The Court specifically found adequately alleged that, during a February 5, 2024 earnings call, CEO Richard Cohen responded to a question concerning Symbotic’s ability to further accelerate deployments by stating that, based upon what the Company then knew, “we can go faster, we can go a lot faster.” The Court concluded that Cohen’s statement was plausibly misleading in light of allegations that Symbotic’s average deployment times had remained stagnant and that the Company’s principal outsourcing partner was experiencing significant performance problems. The Court also permitted claims based upon Cohen’s May 6, 2024 statements concerning Symbotic’s purported acceleration of deployments to proceed.
Significantly, the Court found the allegations sufficient to support a strong inference of scienter [knowing falsity or reckless disregard for the truth] as to Cohen and, by imputation, Symbotic. Among other things, the Court relied upon Cohen’s subsequent disclosure that Symbotic had been hiring personnel in the engineering, procurement and construction area during the six months preceding July 2024 and was considering bringing those functions back in-house.
On February 5, 2025, Symbotic subsequently disclosed that the Company was “still averaging 24 months” to complete deployments and that accelerating deployment times would “take some time.”
The Court denied the motion to dismiss the Section 10(b) and Rule 10b-5 claim against Symbotic and Cohen concerning the allegedly misleading deployment statements. The Court also permitted related Section 20(a) control-person claims against Cohen, Chief Financial Officer Carol J. Hibbard and former Chief Manufacturing and Supply Chain Officer Walter Odisho to proceed.
What Can You Do Now? If you purchased Symbotic Inc. (NASDAQ: SYM) securities on or prior to February 5, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/symbotic-shareholder-investigation/, contact Joshua H. Grabar of Grabar Law Office at jgrabar@grabarlaw.com, or call 267-507-6085 to discuss your rights. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. $SYM #SYM #Symbotic
The Simply Good Foods Company (NASDAQ: SMPL):
Grabar Law Office is investigating claims on behalf of shareholders of The Simply Good Foods Company (NASDAQ: SMPL).
What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased The Simply Good Foods Company (NASDAQ: SMPL) shares before February 24, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit https://grabarlaw.com/the-latest/smpl-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.
What is Alleged? As alleged in a recently filed securities fraud class action Complaint, The Simply Good Foods Company (NASDAQ: SMPL), through certain of its officers, made materially false and misleading statements and/or failed to disclose materially adverse facts pertaining to the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) that Simply Good Foods had lost key managerial personnel following the acquisition of OWYN necessary for the successful integration of the acquired OWYN assets; (2) that Simply Good Foods had materially increased its general and administrative spending to compensate for the loss of key managerial personnel; (3) the addition of a new pea protein supplier for OWYN prior to the acquisition had created significant product quality issues which had negatively impacted the product; (4) Simply Good Foods had engaged in promotional activities for OWYN products above its historical practices, eroding margins; (5) that, in order to stem the margin erosion, Simply Good Foods had cut brand support and marketing, further depressing product sales; (6) as a result of the above, the OWYN acquisition had largely failed to achieve its key strategic goals, the integration of OWYN had run into severe operational and execution problems, and the business and operational results for the OWYN segment had been materially negatively impacted, undermining the acquisitions economic rationale; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
What Can You Do Now? If you purchased The Simply Good Foods Company (NASDAQ: SMPL) shares before February 24, 2024, and still hold shares today, please visit https://grabarlaw.com/the-latest/smpl-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased shares between October 24, 2024 and April 8, 2026, inclusive, you can participate in the class action. #SMPL #SimplyGoodFoods $SMPL
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
